You are here

Article Text

Article menu

Download PDFPDF

Poster Presentation
Toward the identification of genetic determinants of breast cancer immune responsiveness
Free
  1. Ines Simeone1,
  2. Wouter Hendrickx2,
  3. Lance Miller3,
  4. Halima Bensmail1,
  5. Ena Wang2,
  6. Francesco Marincola2,
  7. Michele Ceccarelli1 and
  8. Davide Bedognetti2
  1. Aff1 grid.466961.aQatar Computing Research Institute Doha Qatar
  2. Aff2 grid.467063.00000000403974222Sidra Medical and Research Center Doha Qatar
  3. Aff3 grid.241167.70000000121853318Wake Forest School of Medicine Winston Salem NC USA

https://doi.org/10.1186/2051-1426-3-S1-P1

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Meeting abstracts

    Overlapping immune signatures are observed among cancers with a better prognostic connotation and those with an increased likelihood to respond to immunotherapeutic approaches [1, 2]. Such signatures qualitatively overlap with those detected during other conditions of immune-mediated tissue destruction such as flares of autoimmunity or allograft rejection [3]. These pathways reflect a process characterized by the coordinated activation of interferon stimulated genes (ISGs), the recruitment of cytotoxic cells through the production of specific chemokine ligands (CXCR3 and CCR5 ligands), and the activation of immune effector function (IEF) genes [4]. We refer to these genes as the Immunologic Constant of Rejection (ICR) [2–4]. Here, we tested up-front the prognostic role of the ICR genes in the TCGA (The Cancer Genome Atlas) breast cancer database. We show that ICR genes can segregate breast cancers in different immune phenotypes characterized by distinctive prognostic connotations. Whether the favorable cancer immune phenotype is driven by the intrinsic genetics of the tumor cells is presently unknown. By mining copy number variation, gene-expression, and exome sequencing data we are currently characterizing breast cancer somatic alterations implicated in the development of this favorable cancer immune phenotype. The results of this analysis will be presented and discussed.

    References

    1. 1.↵
      1. Bedognetti D.,
      2. Spivey T. L.,
      3. Zhao Y.,
      4. Uccellini L.,
      5. Tomei S.,
      6. Dudley M. E.,
      7. Ascierto M. L.,
      8. De Giorgi V.,
      9. Liu Q.,
      10. Delogu L. G.,
      11. Sommariva M.,
      12. Sertoli M. R.,
      13. Simon R.,
      14. Wang E.,
      15. Rosenberg S. A.,
      16. Marincola F. M.
      . CXCR3/CCR5 pathways in metastatic melanoma patients treated with adoptive therapy and interleukin-2. British journal of cancer. 2013;109:92412–23. pmcid:3817317 doi:10.1038/bjc.2013.557
      OpenUrlCrossRefPubMed
    2. 2.↵
      1. Galon J.,
      2. Angell H. K.,
      3. Bedognetti D.,
      4. Marincola F. M.
      . The Continuum of Cancer Immunosurveillance: Prognostic, Predictive, and Mechanistic Signatures. Immunity. 2013;39:111–26. doi:10.1016/j.immuni.2013.07.008
      OpenUrlCrossRefPubMedWeb of Science
    3. 3.↵
      1. Spivey T. L.,
      2. Uccellini L.,
      3. Ascierto M. L.,
      4. Zoppoli G.,
      5. De Giorgi V.,
      6. Delogu L. G.,
      7. Engle A. M.,
      8. Thomas J. M.,
      9. Wang E.,
      10. Marincola F. M.,
      11. Bedognetti D.
      . Gene expression profiling in acute allograft rejection: challenging the immunologic constant of rejection hypothesis. J Transl Med. 2011;9:174. pmcid:3213224 doi:10.1186/1479-5876-9-174
      OpenUrlCrossRefPubMed
    4. 4.↵
      1. Wang E.,
      2. Bedognetti D.,
      3. Marincola F. M.
      . Prediction of Response to Anticancer Immunotherapy Using Gene Signatures. J Clin Oncol. 2013;31:192369–2371. doi:10.1200/JCO.2013.49.2157
      OpenUrlFREE Full Text